Treatment of Open-Angle Glaucoma and Ocular Hypertension with the Fixed-Dose Combination of Preservative-Free Tafluprost/Timolol: Clinical Outcomes from Ophthalmology Clinics in Italy.
Francesco OddoneVincenzo ScorciaMichele IesterDario SistoStefano De CillaPaolo BettinCagini CarloMichele FigusGiorgio MarchiniLuca RossettiGemma RossiTommaso SalgarelloGian Luca ScuderiGiovanni Staurenghinull nullPublished in: Clinical ophthalmology (Auckland, N.Z.) (2022)
Italian OAG and OHT patients demonstrated a significant IOP reduction from baseline at Week 4 that was maintained over a 6-month period following a switch from topical PGA or beta-blocker monotherapy to PF tafluprost/timolol FC therapy. Severity of most ocular signs and symptoms was significantly reduced during the study period, and PF tafluprost/timolol FC was generally well tolerated.
Keyphrases
- end stage renal disease
- blood pressure
- chronic kidney disease
- ejection fraction
- primary care
- peritoneal dialysis
- combination therapy
- prognostic factors
- artificial intelligence
- stem cells
- open label
- bone marrow
- randomized controlled trial
- clinical trial
- physical activity
- patient reported outcomes
- mesenchymal stem cells
- double blind
- cataract surgery